Veneno Technologies presented at the 15th Annual Texas Life Science Forum held on November 10, 2026, in Houston, Texas. Co-hosted by the Rice Alliance and BioHouston, the forum brings together life science startups, investors, and leaders from industry and academia. CEO Takatoshi Kuno introduced Veneno’s drug discovery platform, which combines venom-derived disulfide-rich peptides (DRPs) with […]

On November 4, 2026, Veneno Technologies gave a short pitch and presented a poster at “OIST-Lifetime Startup Elevate 2026,” held at the Okinawa Institute of Science and Technology (OIST). CEO Takatoshi Kuno introduced the company’s drug discovery approach using venom-derived disulfide-rich peptides (DRPs). The presentation highlighted how Veneno combines AI with data from its own […]

Veneno Technologies was selected for an accelerator program organized by Ibaraki Prefecture in collaboration with Entrepreneurs Roundtable Accelerator (ERA), a New York-based startup accelerator. The company began participating in the online preparatory program on October 26, 2026, and is scheduled to attend the on-site program in New York in November. Through the program, Veneno will […]

Photo courtesy of LINK-J Veneno Technologies presented at “TOKYO Biotech Day 2026 by TIB CATAPULT/LINK-BioBAY TOKYO” on October 5, 2026, as a startup selected for the second cohort of The Masterclass Program by BioLabs. CEO Kuno introduced Veneno’s approach to discovering medicines from venom-derived peptides. The company’s proprietary Veneno Suite™ platform combines AI with data […]

Veneno Technologies was selected for the second cohort of the J-StarX Biotech Accelerator Program, run by the Japan External Trade Organization (JETRO) and Texas Medical Center (TMC). The company took part in the on-site program in Houston, Texas, from September 21 to October 1, 2026. At the Therapeutics Summit on September 30, CEO Takatoshi Kuno […]

Veneno Technologies Co. Ltd. has been selected for “The Masterclass Program by BioLabs – cohort2,” an acceleration program for life science startups. This program is designed to support startups in the life sciences sector in strengthening their business strategies with a view toward global expansion. Through expert mentoring, pitch coaching, and networking opportunities with corporations […]

Veneno Technologies is pleased to announce the full renewal of our official website, created to communicate our mission and progress more clearly and to a broader audience. The redesigned website features a more intuitive and engaging experience, showcasing the potential of disulfide-rich peptides (DRPs) enabled by our proprietary platform, along with the authentic voices of […]

“Transforming venom, one of nature’s most powerful bioactive substances, into hope for humanity.” That is the bold mission driving Veneno Technologies. Led by President and CEO Takatoshi Kuno, the company is working to break through the limitations of conventional drug discovery with its proprietary peptide engineering technologies. Together with partners around the world, Veneno is […]

In the turbulent world of biotech startups, Veneno Technologies has carved out a distinctive position of its own. At the heart of that achievement lies Director and CTO Tadashi Kimura’s uncompromising devotion to technology, a commitment he has sustained over many years. Since the company’s founding, Kimura has remained at the forefront of its research, […]

Hiroo Tanaka, who is translating deep academic expertise into real-world applications, and Takumi Okamoto, who is channeling the untapped potential of plants into innovation in agriculture. These two young researchers, each with a different area of specialization, are using Veneno Technologies’ platform as a powerful tool to push beyond conventional boundaries and open new frontiers […]